Druggable genomic landscapes of high-grade gliomas

Druggable genomic landscapes of high-grade gliomas

BackgroundDespite the putatively targetable genomic landscape of high-grade gliomas, the long-term survival benefit of genomically-tailored targeted therapies remains discouraging.MethodsUsing glioblastoma (GBM) as a representative example of high-grade gliomas, we evaluated the clonal architecture...

Full description

Bibliographic Details
Main Authors: Paola Ghanem, Maria Fatteh, David Olayinka Kamson, Archana Balan, Michael Chang, Jessica Tao, Jaishri Blakeley, The Johns Hopkins Molecular Tumor Board Investigators, Jenna Canzoniero, Stuart A. Grossman, Kristen Marrone, Karisa C. Schreck, Valsamo Anagnostou, Christine Pratilas, Taxiarchis Botsis, Rena Xian, Chris Gocke, Tseh Ming-Lin, Eitan Halper-Stromberg, Ying Zou, Kent Hardart, Jonathan Spiker, Kory Kreimeyer, Ting He, Katie Fiallos, Dana Petry, Kala Visvanathan, Antonio Wolff, Cesar Santa-Maria, Raquel Nunez, Christian Meyer, John Laterra, Vered Stearns, Karen Smith, Deborah Armstrong, Rachel Karchin, Katerina Karaindrou, Lily Zandi, Marta Majcherska, Faith Too, Monique Makell, Jennifer Lehman, Timsy Wanchoo, Jaime Wehr, Michael Conroy, Selina Shiqing Teh.
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Medicine
Subjects:
genomic landscape
glioblastoma
glioma
actionable mutation
precision oncology
molecular tumor board
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1254955/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1254955/full

Similar Items